Watchlist Price Alert

BioNTech SE (BNTX)

NASDAQ: BNTX · Real-Time Price · USD

106.58

1.66 (1.58%)

At close: Jun 13, 2025, 3:59 PM

106.56

-0.02%

After-hours: Jun 13, 2025, 05:51 PM EDT

1.58% (1D)

Bid	104
Market Cap	25.62B
Revenue (ttm)	2.75B
Net Income (ttm)	-768.64M
EPS (ttm)	-3.64
PE Ratio (ttm)	-29.28
Forward PE	-18.56
Analyst	Buy

Ask	108
Volume	1,263,676
Avg. Volume (20D)	1,213,734
Open	106.36
Previous Close	104.92
Day's Range	105.12 - 107.70
52-Week Range	76.53 - 131.49
Beta	1.28

About BNTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BNTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BNTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 week ago

+18.05%

BioNTech shares are trading higher after the compa... Unlock content with Pro Subscription

3 weeks ago

+4.01%

Shares of vaccine stocks are trading higher following a report indicating FDA advisers will consider if COVID-19 vaccines should target the LP.8.1 subvariant for 2025-2026.

News

1 day ago · schaeffersresearch.com

CureVac Stock Soars on BioNTech Buyout

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

1 day ago · benzinga.com

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.

1 day ago · proactiveinvestors.com

BioNTech boosts cancer mRNA pipeline with CureVac acquisition

BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, e...

1 day ago · barrons.com

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

CureVac stock soared 29% $5.26 in premarket trading immediately following the news.

1 day ago · reuters.com

BioNTech to acquire CureVac in $1.25 billion all-stock deal

German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.

3 days ago · cnbc.com

RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say

Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...

3 days ago · reuters.com

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...

3 days ago · barrons.com

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

4 days ago · investors.com

Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.

Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.

1 week ago · seekingalpha.com

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327...

Load More News